Skip to Content

Galeterone Approval Status

FDA Approved: No
Generic name: galeterone
Company: Tokai Pharmaceuticals, Inc.
Treatment for: Prostate Cancer

Galeterone (TOK-001) is an androgen receptor antagonist and CYP17 lyase inhibitor in development for the treatment of metastatic castration-resistant prostate cancer (CRPC).

Development Status and FDA Approval Process for galeterone

DateArticle
Jun 12, 2012Tokai Pharmaceuticals' Galeterone Receives Fast Track Designation from the FDA for the Treatment of Advanced Prostate Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide